Compare · NTRA vs RDNT
NTRA vs RDNT
Side-by-side comparison of Natera Inc. (NTRA) and RadNet Inc. (RDNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and RDNT operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $39.05B, about 7.9x RDNT ($4.94B).
- Over the past year, NTRA is up 82.2% and RDNT is up 13.2% - NTRA leads by 69.0 points.
- NTRA has been more active in the news (23 items in the past 4 weeks vs 2 for RDNT).
- NTRA has more recent analyst coverage (25 ratings vs 10 for RDNT).
- Company
- Natera Inc.
- RadNet Inc.
- Price
- $273.05+0.03%
- $62.79-0.76%
- Market cap
- $39.05B
- $4.94B
- 1M return
- +24.51%
- +7.89%
- 1Y return
- +82.17%
- +13.20%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 23
- 2
- Recent ratings
- 25
- 10
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
RadNet Inc.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.
Latest NTRA
- Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $280,000 worth of shares (1,000 units at $280.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $4,574,431 worth of shares (16,800 units at $272.29) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 172,294 units (SEC Form 4)
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $818,710 worth of shares (3,000 units at $272.90) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 134,643 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update
- Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
- Director Lynch Thomas J. Jr. was granted 1,905 shares (SEC Form 4)
- Director Marcus Gail Boxer was granted 1,669 shares, increasing direct ownership by 27% to 7,852 units (SEC Form 4)
- Director Botha Roelof was granted 1,691 shares, increasing direct ownership by 58% to 4,585 units (SEC Form 4)
- Director Rosenman Herm was granted 1,677 shares, increasing direct ownership by 39% to 5,927 units (SEC Form 4)
Latest RDNT
- DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite
- Director Swartz David L sold $145,449 worth of shares (2,699 units at $53.89), decreasing direct ownership by 2% to 177,013 units (SEC Form 4)
- Pres & CEO, Digital Health Wesdorp Cornelis sold $276,022 worth of shares (4,750 units at $58.11), decreasing direct ownership by 6% to 69,075 units (SEC Form 4)
- President, CEO Berger Howard G gifted 90 shares (SEC Form 4)
- Pres & CEO-Eastern Operations Forthuber Stephen M sold $2,562,911 worth of shares (44,067 units at $58.16), decreasing direct ownership by 8% to 507,199 units (SEC Form 4)
- RadNet Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- RadNet Secures $250 Million Incremental Term Loan to Fund Strategic Growth Opportunities and Reduces the Interest Rates on its Credit Facility by 0.25%
- DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting
- RadNet Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Swartz David L was granted 2,946 shares, increasing direct ownership by 2% to 179,712 units (SEC Form 4)